Leukemia Dynamics: $170,000 for one year

Re-thinking the box

Gleevec inhibits the BCR-ABL oncogene in childhood and adult leukemias, but the drug is taken for years because “reserve cells” can lead to relapse if gleevec treatment is stopped too early.

This pilot project explores why the gleevec-indifferent reserve cells may exist, based on unexpected preliminary data that leads to a radical new way to think of fusion oncogenes.

Close Menu